Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer

Gemcitabine has been reported to be a potent radiosensitiser in human pancreatic cell lines. This study was conducted to evaluate the efficacy and toxicity of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. In all, 42 patients with pancreatic cancer that was unresectab...

Descripción completa

Detalles Bibliográficos
Autores principales: Okusaka, T, Ito, Y, Ueno, H, Ikeda, M, Takezako, Y, Morizane, C, Kagami, Y, Ikeda, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364779/
https://www.ncbi.nlm.nih.gov/pubmed/15226765
http://dx.doi.org/10.1038/sj.bjc.6602001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364779/
https://www.ncbi.nlm.nih.gov/pubmed/15226765
http://dx.doi.org/10.1038/sj.bjc.6602001

Ejemplares similares